Loading organizations...
Neurofenix is a technology company.
Neurofenix provides a tech-enabled virtual care platform, delivering at-home neurorehabilitation programs for neurological patients. The company offers personalized, engaging, and effective therapy. Its approach leverages neuroplasticity through evidence-based, high-intensity, and high-repetition exercises, supported by virtual therapists and remote monitoring for functional recovery.
Guillem Singla and Dimitrios Athanasiou co-founded Neurofenix, inspired by personal family experiences with stroke recovery. They recognized a critical need for accessible, effective rehabilitation beyond traditional settings. This insight led to a virtual care model, overcoming barriers to deliver consistent, intensive neurorehabilitation remotely.
Neurofenix primarily serves neurological patients, particularly stroke survivors and caregivers, partnering with healthcare organizations. The company seeks equitable access to innovative neurorehabilitation by mitigating obstacles like limited facilities, transport, and waitlists. Its vision is to reshape neurological recovery, empowering individuals to achieve significant improvements from home.
Neurofenix has raised $7.0M across 1 funding round.
Neurofenix has raised $7.0M in total across 1 funding round.
Neurofenix has raised $7.0M in total across 1 funding round.
Neurofenix's investors include Albion VC, HTH, InHealth Ventures.
Neurofenix is a digital health startup developing at-home neurorehabilitation technology, primarily the NeuroBall™, a sensor-equipped device paired with a tablet app for upper limb therapy targeting stroke survivors and other neurological patients.[1][2][3] It serves stroke survivors (B2C) and healthcare providers like ACOs (B2B), solving the problem of inconsistent, low-intensity rehab by enabling high-repetition exercises with real-time feedback, gamification, and virtual therapist support to improve motor skills and independence.[1][3][4] Founded in 2016, the company has raised $7M in Series A funding, operates in the US (Florida, Georgia, Naples) with UK roots, and demonstrates growth through clinical trials showing 20x more repetitions than traditional methods, awards like UK's Best Invention 2018, and expansion plans.[1][2][4]
Neurofenix was co-founded in 2016 by Guillem Singla and Dimitrios Athanasiou at Imperial College London, driven by personal family experiences with stroke recovery and their expertise in biomedical engineering, neurotechnology, and biomechanics.[3] Spotting a critical gap in consistent, intensive at-home rehab for stroke survivors—the leading cause of adult disability—they developed the NeuroBall™, an affordable, easy-to-use device informed by input from over 500 therapists and patients.[1][3][4] Early traction came from Europe's top startup accelerator, UK awards (Royal Academy of Engineering, Nominet Trust, Innovate UK), clinical trials at Brunel University (2017-2021) proving efficacy, and a $7M Series A in 2022 led by AlbionVC to fuel US expansion.[2][3][4]
Neurofenix rides the digital therapeutics and tele-rehab wave, accelerated by COVID-19's shift to virtual care and rising stroke incidence (795K US cases/year).[1][4] Perfect timing aligns with aging populations, rehab access shortages (75% of neuro patients face long-term disability), and payer demand for cost-effective home care over expensive in-clinic sessions.[2][4][5] Market tailwinds include healthtech funding for AI/sensor tech and evidence-based platforms; Neurofenix influences the ecosystem by pioneering scalable, patient-centric models, partnering with providers, and validating tech-rehab via trials, potentially lowering societal stroke costs (economic/social burdens).[1][3][5]
Neurofenix is primed for scale with US rollout (live in Florida, expanding stateside) post-2022 funding, leveraging proven 20x repetition gains and clinician adoption to capture the massive stroke rehab market.[1][4] Trends like AI personalization, broader neuro indications (brain/spinal injuries), and global telehealth growth will propel it; expect partnerships with more ACOs/hospitals and new product lines for full-body rehab.[1][2][3] Its influence could evolve from UK innovator to US leader, democratizing high-quality recovery and reducing disability burdens—echoing its mission to make intensive therapy accessible from day one.[3]
Neurofenix has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in August 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2022 | $7.0M Series A | Albion VC | HTH, InHealth Ventures |